| Old Articles: <Older 5661-5670 Newer> |
|---|
 |
The Motley Fool
May 28, 2009
Brian Orelli |
Best of Both Worlds Fresh blood on Amylin's Board of Directors should be able to offer a new opinion as to how things should change without disrupting the company's progress.   |
The Motley Fool
May 28, 2009
Brian Orelli |
How to Make a Stockpile in Your Portfolio The swine flu has turned out to be a relative dud, hasn't it? It hasn't done much but create a buying opportunity for those who didn't panic. Where should you look to profit from it now? |
The Motley Fool
May 28, 2009
Anders Bylund |
Of Robots and Rocket-Powered Returns Intuitive Surgical is a stock that meets your need for speed and security, all at once. |
The Motley Fool
May 27, 2009
Brian Orelli |
Meet the People Who'll Rule Your Investment Life If you're a drug company investor, that is. The new commissioner and principal deputy commissioner of the Food and Drug Administration introduced themselves and give investors a first look at how they plan to run the agency. |
The Motley Fool
May 27, 2009
Brian Orelli |
A Wrinkle in the Botox Plan The FDA turns down Allergan's label expansion, but it wasn't all bad news. |
The Motley Fool
May 27, 2009
Brian Orelli |
It's Approved! Now Back to Work Now that Bristol-Myers has received approval on its cancer drug Sprycel, it can get back to working on getting it out of its niche market and approved to treat other types of cancer. |
The Motley Fool
May 27, 2009
Brian Orelli |
A Partnership of the Heart Amgen, the large biotech company, exercises its right to license Cytokinetic's cardiac contractility program, including heart failure drug CK-1827452. |
CIO
May 26, 2009
Jarina D'Auria |
How Beth Israel Saved with Voice Recognition Technology Beth Israel Deaconess Medical Center cut patient record turnaround time to under an hour and reduced transcription costs by about 50 percent, saving over $5 million since implementation of voice recognition technology in 2003. |
The Motley Fool
May 26, 2009
Brian Orelli |
When Higher Costs Are a Good Thing The Food and Drug Administration proposed its budget for the next fiscal year, including user fees for pharmaceutical companies. But GlaxoSmithKline, Merck, and the rest of the industry probably won't complain too loudly. |
The Motley Fool
May 26, 2009
Brian Orelli |
A Less-Risky Stem Cell Play Life Technologies is a clear leader in stem cell reagents. |
| <Older 5661-5670 Newer> Return to current articles. |
